Skip header and navigation

Refine By

6 records – page 1 of 1.

The acute effects of inhaled salbutamol on the beat-to-beat variability of heart rate and blood pressure assessed by spectral analysis.

https://arctichealth.org/en/permalink/ahliterature208850
Source
Br J Clin Pharmacol. 1997 Apr;43(4):421-8
Publication Type
Article
Date
Apr-1997
Author
T. Jartti
T. Kaila
K. Tahvanainen
T. Kuusela
T. Vanto
I. Välimäki
Author Affiliation
Department of Paediatrics, Turku University Hospital, Finland.
Source
Br J Clin Pharmacol. 1997 Apr;43(4):421-8
Date
Apr-1997
Language
English
Publication Type
Article
Keywords
Administration, Inhalation
Adrenergic beta-Agonists - administration & dosage - pharmacology
Albuterol - administration & dosage - pharmacology
Baroreflex - drug effects
Blood Pressure - drug effects
Bronchodilator Agents - administration & dosage - pharmacology
Bronchospirometry
Child
Cross-Over Studies
Double-Blind Method
Electrocardiography - drug effects
Female
Finland
Forced Expiratory Flow Rates - drug effects
Heart Rate - drug effects
Humans
Male
Respiratory Function Tests
Supine Position
Abstract
We wanted to study the effects of a 600 micrograms inhaled salbutamol dose on the cardiovascular and respiratory autonomic nervous regulation in eight children suffering from bronchial asthma.
In this randomized, double-blind, placebo-controlled, crossover study we continuously measured electrocardiogram, finger systolic arterial pressure (SAP) and flow-volume spirometry at baseline as well as 20 min and 2 h after the drug inhalation. The R-R interval (the time between successive heart beats) and SAP variabilities were assessed by using spectral analysis. Baroreflex sensitivity was assessed by using cross-spectral analysis.
Salbutamol significantly decreased the total and low frequency (LF) variability of R-R intervals as well as the high frequency (HF) variability of R-R intervals and of SAP. Salbutamol significantly increased the LF/HF ratio of R-R intervals and of SAP, minute ventilation, heart rate and forced pulmonary function in comparison with placebo. The weight of the subjects significantly correlated positively with baroreflex sensitivity and negatively with heart rate after the salbutamol inhalation.
We conclude that the acute salbutamol inhalation decreases cardiovagal nervous responsiveness, increases sympathetic dominance in the cardiovascular autonomic balance, and has a tendency to decrease baroreflex sensitivity in addition to improved pulmonary function.
PubMed ID
9146855 View in PubMed
Less detail

A Canadian multicenter study with Zaditen (ketotifen) in the treatment of bronchial asthma in children aged 5 to 17 years.

https://arctichealth.org/en/permalink/ahliterature230251
Source
J Allergy Clin Immunol. 1989 Sep;84(3):286-96
Publication Type
Article
Date
Sep-1989
Author
A. Rackham
C A Brown
R K Chandra
P. Ho
P E Hoogerwerf
R J Kennedy
A. Knight
H. Langer
J. Milne
D W Moote
Author Affiliation
Clinical Research Department, Sandoz Canada Inc., Dorval, Quebec.
Source
J Allergy Clin Immunol. 1989 Sep;84(3):286-96
Date
Sep-1989
Language
English
Publication Type
Article
Keywords
Adolescent
Asthma - complications - drug therapy - physiopathology
Bronchospirometry
Canada
Child
Child, Preschool
Clinical Trials as Topic
Double-Blind Method
Female
Humans
Ketotifen - adverse effects - therapeutic use
Lung - drug effects - physiopathology
Male
Multicenter Studies as Topic
Random Allocation
Respiratory Function Tests
Statistics as Topic
Theophylline - therapeutic use
Weight Gain - drug effects
Abstract
One hundred thirty-eight children with chronic asthma, requiring daily treatment with bronchodilators, took part in a 7-month, double-blind, multicenter clinical study. Patients were randomized into two groups, and after a 1-month baseline, were administered Zaditen (ketotifen), 1.0 mg twice daily, or an identical placebo for a period of 6 months. After 10 weeks of receiving the study medication, bronchodilator use was reduced or stopped. In the Zaditen-treated group, 60% of the children taking theophylline were able to stop its use completely, compared to 34% of the patients taking placebo (p less than 0.05). Of the patients who were unable to stop taking theophylline, the Zaditen-and placebo-treated groups recorded average dosage reductions of 62% and 26%, respectively. These differences were statistically significant (p less than 0.05). Thus, a high percentage of patients in the placebo-treated group maintained asthma symptom control with theophylline, whereas most of the Zaditen-treated patients could stop using this medication. Although pulmonary function readings improved in both groups, those patients taking Zaditen demonstrated earlier improvement and greater changes from baseline. Significant differences (p less than 0.05) in favor of Zaditen were found for reduction of concomitant medications, patient's global evaluation, physician's clinical evaluations, incidence of emergency room visits for asthma, and upper respiratory tract infections. No unexpected side effects were observed. It is concluded that Zaditen is an effective medication for long-term control of asthma in children.
Notes
Comment In: J Allergy Clin Immunol. 1990 Aug;86(2):274-52132736
PubMed ID
2674262 View in PubMed
Less detail

[Complex bronchial treatment of children with unspecific chronic lung diseases]

https://arctichealth.org/en/permalink/ahliterature44136
Source
Pediatr Akus Ginekol. 1970 Mar-Apr;2:14-5
Publication Type
Article

[Organization of the Functional-Bronchological Service at the District Antituberculosis Dispensary].

https://arctichealth.org/en/permalink/ahliterature252856
Source
Probl Tuberk. 1975;(5):5-9
Publication Type
Article
Date
1975

6 records – page 1 of 1.